Response of brain metastases from breast cancer to megestrol acetate: a case report.

Abstract

A 56 year old women was treated with megestrol acetate (Megace) 40 mg p.o. q.i.d. for her cerebellar metastasis of primary adenocarcinoma of the breast. She had previously undergone two surgical resections of her brain metastasis, and a course of radiotherapy. After failing to tolerate tamoxifen therapy, she received Megace, with marked improvement in her cerebellar tumor on CT scans. Despite good control of her brain tumor with Megace, she developed progressive neurological symptoms thought to be due to meningeal carcinomatosis, and died two years after initiating Megace therapy. We conclude that Megace could potentially be beneficial in some patients with brain metastases from adenocarcinoma of the breast.

• Authors: D J Stewart, S Dahrouge
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 24 Issue 3 Pg. 299-301 ( 1995) ISSN: 0167-594X [Print] United States
• PMID: 7595761 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Megestrol
• Megestrol Acetate

Topics

• Adenocarcinoma (drug therapy, pathology, secondary)
• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (pathology)
• Cerebellar Neoplasms (drug therapy, secondary)
• Combined Modality Therapy
• Disease Progression
• Fatal Outcome
• Female
• Humans
• Megestrol (analogs & derivatives, therapeutic use)
• Megestrol Acetate
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)